Ascendis Pharma A/S (NASDAQ: ASND) is one of 306 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its competitors? We will compare Ascendis Pharma A/S to related businesses based on the strength of its valuation, risk, dividends, analyst recommendations, earnings, profitability and institutional ownership.
This table compares Ascendis Pharma A/S and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Ascendis Pharma A/S||-2,977.70%||-67.76%||-60.93%|
|Ascendis Pharma A/S Competitors||-5,310.00%||-487.10%||-42.46%|
Valuation and Earnings
This table compares Ascendis Pharma A/S and its competitors top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Ascendis Pharma A/S||$5.10 million||-$75.80 million||-11.22|
|Ascendis Pharma A/S Competitors||$288.09 million||$35.08 million||150.27|
Ascendis Pharma A/S’s competitors have higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Institutional & Insider Ownership
65.0% of Ascendis Pharma A/S shares are held by institutional investors. Comparatively, 50.0% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 40.0% of Ascendis Pharma A/S shares are held by insiders. Comparatively, 17.0% of shares of all “Bio Therapeutic Drugs” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
This is a breakdown of recent ratings for Ascendis Pharma A/S and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Ascendis Pharma A/S||0||1||5||0||2.83|
|Ascendis Pharma A/S Competitors||791||3132||11435||227||2.71|
Ascendis Pharma A/S currently has a consensus target price of $36.95, indicating a potential upside of 2.27%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 41.34%. Given Ascendis Pharma A/S’s competitors higher possible upside, analysts clearly believe Ascendis Pharma A/S has less favorable growth aspects than its competitors.
Risk & Volatility
Ascendis Pharma A/S has a beta of 0.66, suggesting that its share price is 34% less volatile than the S&P 500. Comparatively, Ascendis Pharma A/S’s competitors have a beta of 5.91, suggesting that their average share price is 491% more volatile than the S&P 500.
About Ascendis Pharma A/S
Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications. In addition to TransCon hGH, the Company has developed a pipeline of long-acting prodrug product candidates, such as TransCon Treprostinil for the treatment of pulmonary arterial hypertension (PAH), TransCon Peptides for the treatment of diabetes and TransCon Ranibizumab for the treatment of ophthalmology. It is also using its TransCon technology platform to develop TransCon Parathyroid Hormone (TransCon PTH) for hypoparathyroidism, a rare endocrine disorder of calcium and phosphate metabolism.
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.